Disclaimer: The information, documents and graphic depictions (the "Information") published on this Web site are the property of LIfT BioSciences Ltd. LIfT BioSciences assumes no responsibility for errors or omissions in the Information on this website. In no event shall LIfT BioSciences be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of this Web site or the Information. LIfT BioSciences reserves the right to make additions, deletions, or modification to the Information on the Web site at any time without prior notice.

  • CEO's Linked-in
  • CEO's Twitter
  • LIfTBio on Facebook

©2016 LIfT BioSciences Ltd

Please reload

Recent Posts

LIfT BioSciences Wins the Support of The European Institute for Innovation & Technology

February 12, 2019

1/7
Please reload

Featured Posts

LIfT BioSciences Partners Kings College London for Cell Therapy Development

December 9, 2016

 

LIfT BioSciences has entered into partnership with Kings College London's Cell Therapy Unit and Clinical Research Facility to research and develop its breakthrough LIfT Cell Therapy for Pancreatic Cancer.

 

The Cell Therapy Unit is the largest manufacturing facility of its kind in either academia or industry in Europe, with capacity to produce more than six final products simultaneously and a total of around a thousand therapies per year. The unit is financially supported through both the NHS and NIHR. This is a complex and sophisticated Good Manufacturing Practice (GMP) Unit built to the exacting standards required to meet the licensing requirements of the Medicines and Healthcare products Regulatory Agency (MHRA) for the manufacture of human cell and gene based therapies.

 

The Clinical Research Facility spans three floors with a further standalone unit. Each area has been designed and built to compliment the other in terms of ability to offer a unique and neutral space to carry out trials in a dedicated research setting.

 

As part of the arrangement Professor Farzin Farzaneh, an expert in Molecular Medicine and Cell Therapies leading the team at King’s College London, has joined LIfTBioSciences Advisory Board. Professor Farzaneh has been running GMP facilities for the production of cell and gene therapy based investigational medicinal products since 2001.

 

Alex Blyth, CEO, LIfT BioSciences commented that "the partnership builds on our strategy to partner with the best institutions in Europe to bring this breakthrough therapy to patients as fast and effectively as possible".  

 

 

Share on Facebook
Share on Twitter
Please reload

Follow Us

I'm busy working on my blog posts. Watch this space!

Please reload

Search By Tags